154 related articles for article (PubMed ID: 37593196)
1. Comprehensive Analysis of SLC35A2 in Pan-Cancer and Validation of Its Role in Breast Cancer.
Sun X; Yuan Z; Zhang L; Ren M; Yang J; Xu Y; Hao J
J Inflamm Res; 2023; 16():3381-3398. PubMed ID: 37593196
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
3. SLC35A2 expression drives breast cancer progression via ERK pathway activation.
Yang X; Tao Y; Xu Y; Cai W; Shao Q
FEBS J; 2024 Apr; 291(7):1483-1505. PubMed ID: 38143314
[TBL] [Abstract][Full Text] [Related]
4. Solute carrier family 35 member A2 (SLC35A2) is a prognostic biomarker and correlated with immune infiltration in stomach adenocarcinoma.
Huang Z; Yang H; Lao J; Deng W
PLoS One; 2023; 18(7):e0287303. PubMed ID: 37467193
[TBL] [Abstract][Full Text] [Related]
5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
6. SLC35A2 expression is associated with HER2 expression in breast cancer.
Wang Y; Peng X; Wu M; Wang B; Chen T; Zhan X
Discov Oncol; 2024 Apr; 15(1):124. PubMed ID: 38639872
[TBL] [Abstract][Full Text] [Related]
7. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
8.
Ke P; Bao X; Liu C; Zhou B; Huo M; Chen Y; Wang X; Wu D; Ma X; Liu D; Chen S
Transl Cancer Res; 2022 Oct; 11(10):3491-3505. PubMed ID: 36388050
[TBL] [Abstract][Full Text] [Related]
9. BOP1 Used as a Novel Prognostic Marker and Correlated with Tumor Microenvironment in Pan-Cancer.
Li W; Song P; Zhao M; Gao L; Xie J; You C
J Oncol; 2021; 2021():3603030. PubMed ID: 34603446
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
[TBL] [Abstract][Full Text] [Related]
11. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
[TBL] [Abstract][Full Text] [Related]
12. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
13. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
14. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
15. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
16. A pan-cancer analysis of the expression and molecular mechanism of DHX9 in human cancers.
Wang Y; Guo Y; Song Y; Zou W; Zhang J; Yi Q; Xiao Y; Peng J; Li Y; Yao L
Front Pharmacol; 2023; 14():1153067. PubMed ID: 37214432
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation.
Cheng H; Wang S; Gao D; Yu K; Chen H; Huang Y; Li M; Zhang J; Guo K
Cell Oncol (Dordr); 2023 Apr; 46(2):283-297. PubMed ID: 36454514
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
20. Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis.
Wang ZQ; Wu ZX; Wang ZP; Bao JX; Wu HD; Xu DY; Li HF; Xu YY; Wu RX; Dai XX
BMC Cancer; 2024 Mar; 24(1):353. PubMed ID: 38504158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
